CCM
TEVA icon

Camber Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Camber Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,150,000
Closed -$104M – 43
2023
Q3 		$104M Buy
10,150,000
+1,650,000
+19% +$15.4M 3.41% 11
2023
Q2 		$64M Buy
8,500,000
+5,500,000
+183% +$44.6M 2.08% 18
2023
Q1 		$26.6M Sell
3,000,000
-4,000,000
-57% -$39.6M 0.82% 22
2022
Q4 		$63.8M Sell
7,000,000
-500,000
-7% -$4.36M 2.19% 16
2022
Q3 		$60.5M Buy
7,500,000
+4,750,000
+173% +$42M 1.85% 21
2022
Q2 		$20.7M Hold
2,750,000
– – 0.9% 26
2022
Q1 		$25.8M Hold
2,750,000
– – 0.93% 26
2021
Q4 		$22M Sell
2,750,000
-2,250,000
-45% -$20.3M 0.76% 29
2021
Q3 		$48.7M Sell
5,000,000
-500,000
-9% -$4.68M 1.5% 26
2021
Q2 		$54.5M Hold
5,500,000
– – 1.83% 25
2021
Q1 		$63.5M Buy
5,500,000
+1,000,000
+22% +$11.5M 2.18% 17
2020
Q4 		$43.4M Hold
4,500,000
– – 1.52% 21
2020
Q3 		$40.5M Buy
4,500,000
+2,500,000
+125% +$26.4M 2.14% 18
2020
Q2 		$24.7M Buy
+2,000,000
New +$22.6M 1.41% 20
2020
Q1 		– Sell
-2,000,000
Closed -$19.6M – 33
2019
Q4 		$19.6M Buy
+2,000,000
New +$17.9M 1% 25
2019
Q3 		– Sell
-6,500,000
Closed -$60M – 37
2019
Q2 		$60M Buy
6,500,000
+3,000,000
+86% +$36.2M 2.8% 15
2019
Q1 		$54.9M Buy
+3,500,000
New +$61.7M 2.73% 16
2017
Q3 		– Sell
-5,266,450
Closed -$175M – 29
2017
Q2 		$175M Buy
5,266,450
+50,000
+1% +$1.55M 8.52% 2
2017
Q1 		$167M Buy
5,216,450
+492,000
+10% +$16.8M 6.79% 2
2016
Q4 		$171M Buy
4,724,450
+724,450
+18% +$28.9M 8.92% 1
2016
Q3 		$184M Buy
4,000,000
+1,130,000
+39% +$59M 8.09% 2
2016
Q2 		$144M Buy
2,870,000
+620,000
+28% +$33M 6.97% 2
2016
Q1 		$120M Buy
2,250,000
+450,000
+25% +$26.4M 7.05% 1
2015
Q4 		$118M Sell
1,800,000
-200,000
-10% -$12.4M 7.63% 1
2015
Q3 		$113M Buy
2,000,000
+250,000
+14% +$16.2M 9.67% 1
2015
Q2 		$103M Buy
1,750,000
+100,000
+6% +$6.17M 7.04% 1
2015
Q1 		$103M Sell
1,650,000
-100,000
-6% -$5.81M 7.34% 2
2014
Q4 		$101M Hold
1,750,000
– – 6.69% 2
2014
Q3 		$94.1M Hold
1,750,000
– – 8.84% 1
2014
Q2 		$91.7M Buy
1,750,000
+100,000
+6% +$5.11M 6.01% 2
2014
Q1 		$87.2M Sell
1,650,000
-350,000
-18% -$16.2M 6.83% 2
2013
Q4 		$80.2M Hold
2,000,000
– – 7.07% 2
2013
Q3 		$75.6M Buy
2,000,000
+1,250,000
+167% +$48.8M 7.92% 2
2013
Q2 		$29.4M Buy
+750,000
New +$29.2M 3.02% 14

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Camber Capital Management's TEVA Position: Q4 2023 in Review

Camber Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2023, closing a stake of 10,150,000 shares — an estimated $104M sold.

Camber Capital Management first reported a position in TEVA in Q2 2013 and held it in 34 quarters. The position peaked at $184M in Q3 2016. 447 funds tracked by Wall St. Rank hold TEVA as of Q4 2023.

  • Camber Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Camber Capital Management sold 10,150,000 Teva Pharmaceuticals shares in Q4 2023, an estimated $104M.
  • Camber Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 34 quarters.
  • Camber Capital Management's Teva Pharmaceuticals position peaked at $184M in Q3 2016.
  • 447 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2023.

Based on Camber Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.